ASH 2021 Axicabtagene ciloleucel: potential new second-line standard of care for patients with relapsed... Read more
ASH 2021 Mosunetuzumab: effective and well-tolerated in the treatment of relapsed/refractory follicular... Read more
ASH 2021 Daratumumab plus VCd as a new standard of care for patients with newly diagnosed light-chain a... Read more
ASH 2020 Subcutaneous daratumumab plus pomalidomide-dexamethasone: an effective treatment option for M... Read more
ASH 2020 Dose-escalation of oral azacitidine provides clinical benefit to acute myeloid leukaemia patie... Read more
